InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference
2024年5月22日 - 7:45PM
ビジネスワイヤ(英語)
InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the
leading medical cannabis company outside of North America, today
announced that it will participate in the Canaccord Genuity 8th
Annual Global Cannabis Conference. The conference is scheduled for
tomorrow, May 23, 2024, at the Westin NY Grand Central Hotel in New
York City.
This prestigious event will bring together senior management
teams from leading cannabis companies including InterCure CEO Alex
Rabinovitch, to engage in panel discussions, fireside chats, and
one-on-one meetings. For more information about the event please
refer to the following link:
https://www.canaccordgenuity.com/capital-markets/events-and-conferences/cg-8th-annual-global-cannabis-conference/
About InterCure (dba Canndoc) InterCure (dba Canndoc)
(NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest
growing cannabis company outside of North America. Canndoc, a
wholly owned subsidiary of InterCure, is Israel’s largest licensed
cannabis producer and one of the first to offer Good Manufacturing
Practices (GMP) certified and pharmaceutical-grade medical cannabis
products. InterCure leverages its market leading distribution
network, best in class international partnerships and a high-margin
vertically integrated "seed-to-sale" model to lead the fastest
growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522762595/en/
InterCure Ltd. Amos Cohen, Chief Financial Officer
amos@intercure.co
Intercure (NASDAQ:INCR)
過去 株価チャート
から 5 2024 まで 6 2024
Intercure (NASDAQ:INCR)
過去 株価チャート
から 6 2023 まで 6 2024